Crossmark

Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma

Crossref DOI link: https://doi.org/10.1007/s11864-018-0522-4

Published Online: 2018-01-18

Published Print: 2018-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nandagopal, Lakshminarayanan

Naik, Gurudatta

Sonpavde, Guru
License Information

Text and Data Mining valid from 2018-01-01
More Information

Article History

First Online: 18 January 2018

Compliance with Ethical Standards

:

: Lakshminarayanan Nandagopal declares that he has no conflict of interest.Gurudatta Naik declares that he has no conflict of interest.Guru Sonpavde is supported by grants to his institution from Boehringer-Ingelheim, Bayer, Onyx-Amgen, Merck, Pfizer, and Celgene; has served as a consultant for Pfizer, Genentech, Novartis, Merck, Sanofi, Astrazeneca, Exelixis, Bristol-Myers-Squibb, Janssen, Amgen, and the National Comprehensive Cancer Network (NCCN); has served as an author for Uptodate; and has served as a guest speaker for Physicians’ Education Resource (PER) and OncLive.

: This article does not contain any studies with human or animal subjects performed by any of the authors.